203 related articles for article (PubMed ID: 11095447)
21. Effect of administration of thyroxine on the risk of postpartum recurrence of hyperthyroid Graves' disease.
Hashizume K; Ichikawa K; Nishii Y; Kobayashi M; Sakurai A; Miyamoto T; Suzuki S; Takeda T
J Clin Endocrinol Metab; 1992 Jul; 75(1):6-10. PubMed ID: 1642700
[TBL] [Abstract][Full Text] [Related]
22. Changes in serum TSH and T4 after T3 suppression tests in patients treated for hyperthyroidism due to Graves' disease.
Suematsu H; Tamai H; Esaki M; Kurokawa N; Aoki H; Matsuzuka F; Miyauchi A; Kuma K
J Clin Endocrinol Metab; 1977 Nov; 45(5):1013-8. PubMed ID: 579181
[No Abstract] [Full Text] [Related]
23. Quantitative analyses of urinary pyridinoline and deoxypyridinoline excretion in patients with hyperthyroidism.
Ohishi T; Takahashi M; Kushida K; Horiuchi K; Ishigaki S; Inoue T
Endocr Res; 1992; 18(4):281-90. PubMed ID: 1473521
[TBL] [Abstract][Full Text] [Related]
24. High levels of serum soluble interleukin-2 receptors in hyperthyroid patients: correlation with serum thyroid hormones and independence from the etiology of the hyperthyroidism.
Koukkou E; Panayiotidis P; Alevizou-Terzaki V; Thalassinos N
J Clin Endocrinol Metab; 1991 Oct; 73(4):771-6. PubMed ID: 1909702
[TBL] [Abstract][Full Text] [Related]
25. Aggravation of thyrotoxicosis in early pregnancy and after delivery in Graves' disease.
Amino N; Tanizawa O; Mori H; Iwatani Y; Yamada T; Kurachi K; Kumahara Y; Miyai K
J Clin Endocrinol Metab; 1982 Jul; 55(1):108-12. PubMed ID: 6896207
[TBL] [Abstract][Full Text] [Related]
26. [The prognostic application of thyroid volume determination in patients with Graves' disease].
Sakane S
Nihon Naibunpi Gakkai Zasshi; 1990 May; 66(5):543-56. PubMed ID: 1696557
[TBL] [Abstract][Full Text] [Related]
27. Circulating soluble interleukin 2 receptor concentration is increased in both immunogenic and nonimmunogenic hyperthyroidism.
Mariotti S; Caturegli P; Barbesino G; Del Prete GF; Chiovato L; Pinchera A
J Endocrinol Invest; 1991 Oct; 14(9):777-81. PubMed ID: 1761814
[TBL] [Abstract][Full Text] [Related]
28. Lower serum free thyroxine (T4) levels in painless thyroiditis compared with Graves' disease despite similar serum total T4 levels.
Shigemasa C; Abe K; Taniguchi S; Mitani Y; Ueda Y; Adachi T; Urabe K; Tanaka T; Yoshida A; Mashiba H
J Clin Endocrinol Metab; 1987 Aug; 65(2):359-63. PubMed ID: 3110204
[TBL] [Abstract][Full Text] [Related]
29. Bone turnover in overt and subclinical hyperthyroidism due to autonomous thyroid adenoma.
De Menis E; Da Rin G; Roiter I; Legovini P; Foscolo G; Conte N
Horm Res; 1992; 37(6):217-20. PubMed ID: 1292974
[TBL] [Abstract][Full Text] [Related]
30. Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission.
García-Mayor RV; Páramo C; Luna Cano R; Pérez Mendez LF; Galofré JC; Andrade A
J Endocrinol Invest; 1992 Dec; 15(11):815-20. PubMed ID: 1283984
[TBL] [Abstract][Full Text] [Related]
31. Serum free triiodothyronine to free thyroxine ratio enables early prediction of the outcome of antithyroid drug therapy in patients with Graves' hyperthyroidism.
Tajiri J; Noguchi S; Morita M; Tamaru M; Murakami N; Kato R
Endocrinol Jpn; 1991 Dec; 38(6):683-7. PubMed ID: 1726635
[TBL] [Abstract][Full Text] [Related]
32. The serum concentration and activity of DPP4 is positively related with the severity of hyperthyroidism in patients with Graves' disease.
Chang X; Ding X; Wang J; Cai Q; Wang G; Liu J
Ann Med; 2023 Dec; 55(1):2226910. PubMed ID: 37350750
[TBL] [Abstract][Full Text] [Related]
33. Serum levels of calcium and parathyroid hormone after subtotal thyroid resection for Graves' disease.
Aagaard J; Blichert-Toft M; Christiansen C
Acta Med Scand; 1982; 211(4):261-4. PubMed ID: 6896600
[TBL] [Abstract][Full Text] [Related]
34. Serum interferon levels associated with the disease activity in women with overt Graves' disease.
Cheng CW; Fang WF; Tang KT; Lin JD
Cytokine; 2021 Feb; 138():155353. PubMed ID: 33121876
[TBL] [Abstract][Full Text] [Related]
35. The clinical value of serum triiodothyronine, thyroxine and thyrotropin estimations during medical antithyroid treatment.
Rogowski P; Friis T; Kirkegaard C; Siersbaek-Nielsen K
Acta Med Scand; 1977; 202(1-2):93-6. PubMed ID: 70965
[TBL] [Abstract][Full Text] [Related]
36. [The role of circulating immune complexes in the pathogenesis of Graves' disease].
Funauchi M
Nihon Naibunpi Gakkai Zasshi; 1983 Dec; 59(12):1912-27. PubMed ID: 6325260
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the timing to reduce the initial dose of antithyroid drugs in patients with Graves' disease.
Nagayama Y; Eishima K; Hirayu H; Yamashita S; Ashizawa K; Matsuo K; Inoue S; Harakawa S; Morita S; Izumi M
Endocrinol Jpn; 1990 Dec; 37(6):769-75. PubMed ID: 1714371
[TBL] [Abstract][Full Text] [Related]
38. Comparison of LATS activity and TSH receptor antibody in Graves' disease.
Kajita Y; Nakajima Y; Ishida M; Ura Y; Ochi Y; Miyazaki T; Hachiya T; Ijichi H
Endocrinol Jpn; 1984 Jun; 31(3):369-74. PubMed ID: 6094169
[TBL] [Abstract][Full Text] [Related]
39. Effect of antithyroid treatment on calcium-phosphorus metabolism in hyperthyroidism. I: Chemical quantities in serum and urine.
Mosekilde L; Christensen MS; Melsen F; Sørensen NS
Acta Endocrinol (Copenh); 1978 Apr; 87(4):743-50. PubMed ID: 580520
[TBL] [Abstract][Full Text] [Related]
40. Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism.
Mosekilde L; Melsen F; Bagger JP; Myhre-Jensen O; Schwartz Sorensen N
Acta Endocrinol (Copenh); 1977 Jul; 85(3):515-25. PubMed ID: 577336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
